Estrogenic effects of the synthetic aminoestrogen 17 beta-(5-hydroxy-1-pentylamino)-1,3,5(10)-estratrien-3-ol (pentolame).
In this study, we investigated the effects of pentolame, a 17 beta-aminoestrogen derivative, upon coagulation, serum LH, pituitary progestin receptors, uterine weight, and endometrium morphological changes in the castrated female rat. Groups of animals were subcutaneously (s.c.) injected with either estradiol (E2) (0.1 up to 1000 micrograms/animal), pentolame (1 up to 1000 micrograms/animal), or the vehicle alone daily for 5 consecutive days starting 2 weeks following ovariectomy. Administration of pentolame (10 to 1000 micrograms/animal) increased significantly (p < 0.05) the blood clotting time when compared with that obtained in the group of control animals (EC50 582 micrograms). Pentolame (500 and 1000 micrograms/rat for 5 days) caused a significant inhibition (p < 0.01) of serum LH levels (IC50 860 micrograms), which remained suppressed until Day 5 post last injection. In addition, treatment with pentolame was able to restore in the castrated female rat the presence of specific estrogen-dependent progestin binding sites at the anterior pituitary level. The affinity constants and the number of binding sites of pentolame-induced progestin receptors were similar to those obtained with estradiol at equipotent doses (860 micrograms vs. 1 microgram/animal, respectively). Administration of the 17 beta-aminoestrogen derivative resulted in a significant increase in uterine weight (EC50 420 micrograms) and endometrial characteristics were indistinguishable from those observed in the group of rats treated with E2.
Lemus
A E
AE
Department of Reproductive Biology, UAM-Iztapalapa, Universidad Nacional Autónoma de México, Mexico City.
Jaimez
R
R
Lemini
C
C
Menjivar
M
M
Silva
G
G
Rubio-Poo
C
C
Valenzuela
F
F
Larrea
F
F
D000605:Amino Alcohols / Q000008:administration & dosage*; D000818:Animals; D001777:Blood Coagulation / Q000187:drug effects; D045166:Estradiol Congeners / Q000494:pharmacology*; D004963:Estrenes / Q000008:administration & dosage*; D005260:Female; D007279:Injections, Subcutaneous; D007986:Luteinizing Hormone / Q000097:blood / Q000187:drug effects; D009929:Organ Size / Q000187:drug effects; D010052:Ovariectomy; D010903:Pituitary Gland, Anterior / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D011980:Receptors, Progesterone / Q000096:biosynthesis / Q000187:drug effects; D014599:Uterus / Q000187:drug effects / Q000254:growth & development
D000605:Amino Alcohols; D045166:Estradiol Congeners; D004963:Estrenes; D011980:Receptors, Progesterone; C083220:pentolame; D007986:Luteinizing Hormone